ALISA SCHOLL: Open Payments
NPI 1518539238 · TERRE HAUTE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,089 in 62 payments from 22 companies in 2025. Trend: 2023 $0 · 2024 $152 · 2025 $2,089
Food & beverage: $2,089
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $447 |
| Novo Nordisk Inc | 10 | $310 |
| Lilly USA, LLC | 7 | $228 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $153 |
| Boston Scientific Corporation | 2 | $152 |
| GlaxoSmithKline, LLC. | 2 | $137 |
| Kowa Pharmaceuticals America, Inc. | 1 | $125 |
| Amgen Inc. | 5 | $78 |
| Novartis Pharmaceuticals Corporation | 3 | $66 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $63 |
Products named: BREZTRI, FARXIGA, Ozempic, CAPLYTA, WATCHMAN FLX, ZORYVE, AREXVY, ZEPBOUND.
Industry payments across IN — which companies pay providers there.
